Castle Biosciences, Inc. (CSTL)
| Market Cap | 1.02B +58.3% |
| Revenue (ttm) | 357.28M +3.2% |
| Net Income | -19.42M |
| EPS | -0.65 |
| Shares Out | 30.55M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 372,588 |
| Open | 34.02 |
| Previous Close | 34.26 |
| Day's Range | 32.80 - 34.28 |
| 52-Week Range | 17.72 - 44.28 |
| Beta | 0.97 |
| Analysts | Strong Buy |
| Price Target | 44.00 (+31.34%) |
| Earnings Date | Jul 30, 2026 |
About CSTL
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasi... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for CSTL stock is "Strong Buy." The 12-month stock price target is $44.0, which is an increase of 31.34% from the latest price.
News
Castle Biosciences to Participate in Upcoming Investor Conferences
FRIENDSWOOD, Texas, Aug. 20, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executi...
Castle Biosciences approved for dual listing on Nasdaq Texas
Castle Biosciences (CSTL) announced that it has been approved to have its common stock dually listed on Nasdaq Texas, a new exchange headquartered in Dallas. Castle will maintain its primary…
Castle Biosciences Approved for Dual Listing on Nasdaq Texas
FRIENDSWOOD, Texas, Aug. 17, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been...
Castle Biosciences Transcript: Canaccord Genuity's 46th Annual Growth Conference
Strong growth in melanoma and GI cancer testing is driving raised guidance, with continued physician education and expanded sales force supporting further penetration. New product launches and reimbursement milestones are expected to contribute to revenue growth, with adjusted EBITDA projected to remain positive through 2027.
Castle Biosciences price target raised to $44 from $40 at BTIG
BTIG raised the firm’s price target on Castle Biosciences (CSTL) to $44 from $40 and keeps a Buy rating on the shares after “a strong Q2 beat” and another guidance…
Castle Biosciences price target raised to $44 from $40 at BTIG
BTIG raised the firm’s price target on Castle Biosciences (CSTL) to $44 from $40 and keeps a Buy rating on the shares. The company delivered a strong Q2 beat on…
Castle Biosciences price target raised to $57 from $52 at Lake Street
Lake Street raised the firm’s price target on Castle Biosciences (CSTL) to $57 from $52 and keeps a Buy rating on the shares following a Q2 “blowout” accompanied by a…
Castle Biosciences price target lowered to $36 from $43 at Baird
Baird lowered the firm’s price target on Castle Biosciences (CSTL) to $36 from $43 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results.
Castle Biosciences Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 20% year-over-year to $103.5 million, driven by strong test volume growth in core products. Full-year revenue guidance was raised to $365–$375 million, with positive adjusted EBITDA expected for 2026. Robust cash reserves support ongoing investments in growth and pipeline expansion.
Castle Biosciences Earnings release: Q2 2026
Castle Biosciences released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Castle Biosciences Quarterly report: Q2 2026
Castle Biosciences has published its Q2 2026 quarterly earnings report on July 30, 2026.
Castle Biosciences Slides: Q2 2026
Castle Biosciences has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Castle Biosciences reports Q2 EPS (7c), consensus (41c)
Reports Q2 revenue $103.5M, consensus $86.24M. “The Castle Biosciences (CSTL) team delivered another outstanding quarter,” said CEO Derek Maetzold. “We believe our strong growth through the first half...
Castle Biosciences raises 2026 revenue view to $365M-$375M from $345M-$355M
2026 consensus $352.29M. Sees positive adjusted EBITDA for 2026 and both Q3 and Q4.
Castle Biosciences Slides: Corporate presentation
Castle Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on July 30, 2026.
Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference
FRIENDSWOOD, Texas, July 22, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executi...
Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test
Approval expands access to Castle's precision medicine test designed to guide systemic treatment decision making in patients with moderate-to-severe atopic dermatitis FRIENDSWOOD, Texas, July 14, 2026...
Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026
FRIENDSWOOD, Texas, July 9, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will rele...
Castle Biosciences’ i31-SLNB outperforms MIA nomogram in lymph node biopsy
Castle Biosciences (CSTL) announced the publication of a prospective, multicenter study in Dermatology and Therapy demonstrating that DecisionDx-Melanoma’s integrated sentinel lymph node biopsy test r...
DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy
Newly published prospective study shows DecisionDx-Melanoma's i31-SLNB test result more accurately identifies patients at low and high risk of sentinel lymph node (SLN) positivity than the Melanoma In...
Roth starts Castle Biosciences at Buy, notes quality revenue growth outlook
Roth Capital initiated coverage of Castle Biosciences (CSTL) with a Buy rating and $40 price target The firm believes Castle should be owned for its quality revenue growth outlook over…
Castle Biosciences initiated with a Buy at Roth Capital
Roth Capital initiated coverage of Castle Biosciences (CSTL) with a Buy rating and $40 price target
Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal
Stokes was one of 22 financial leaders recognized in the Greater Houston area FRIENDSWOOD, Texas, June 23, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health thro...
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FRIENDSWOOD, Texas, June 19, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on June 15,...
Castle Biosciences’ TissueCypher Test surpasses 100,000 orders
Castle Biosciences (CSTL)’ TissueCypher Barrett’s Esophagus Test has surpassed 100,000 clinical test orders. TissueCypher is an AI-derived precision medicine test designed to predict a patient’s five-...